1. Academic Validation
  2. Antitumor activity of opiorphin, sialorphin and their conjugates with a peptide klaklakklaklak

Antitumor activity of opiorphin, sialorphin and their conjugates with a peptide klaklakklaklak

  • J Pept Sci. 2016 Nov;22(11-12):723-730. doi: 10.1002/psc.2936.
Elżbieta Kamysz 1 Ryszard Smolarczyk 2 Tomasz Cichoń 2 Magdalena Jarosz-Biej 2 Emilia Sikorska 1 Małgorzata Sobocińska 1 Maciej Jaśkiewicz 3 Wojciech Kamysz 3
Affiliations

Affiliations

  • 1 University of Gdansk, Faculty of Chemistry, Gdansk, Poland.
  • 2 Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland.
  • 3 Medical University of Gdansk, Faculty of Pharmacy, Gdansk, Poland.
Abstract

This is the study on the effect of opiorphin, sialorphin and their analogs on antitumor activity. We demonstrated that conjugation of opiorphin and sialorphin with a proapoptotic, antimicrobial peptide klak (klaklakklaklak) led to compounds (opio-klak and sialo-klak) that were cytotoxic against Cancer cells (LN18, PC3, A549, HCT116 and B10-F16) in the MTT test. The conjugated analogs were designed to increase the effectiveness of the peptide. The opio-klak derivative was the most effective in the in vitro assays and led to a decrease in viability of Cancer cells over time as compared with that of untreated controls. In contrast, treatment with either the untargeted klak peptide or opiorphin as a negative control led to a negligible loss in viability. Antitumor effect of the opio-klak was also observed in vivo in murine melanoma tumor-bearing mice. Cessation of peptide administration resulted in tumor regrowth. Our results are seemingly valuable for the development of opiorphin analogs with potential clinical applications. Copyright © 2016 European Peptide Society and John Wiley & Sons, Ltd.

Keywords

antitumor activity; circular dichroism; melanoma; opiorphin; peptide synthesis; sialorphin.

Figures